sci2sci
An AI data-governance platform for biotech and pharma that connects fragmented research and operational data, preserves its lineage and permissions, and grounds AI-assisted work in verifiable evidence.
€1.2MPre-Seed
ParticipantS
Superangels
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
Superangels is the Munich early-stage investor whose official portfolio identifies Sodex, Sedivention and sci2sci.
Recorded funding activity
Sodex develops construction-site technology. Sedivention develops a cryoablation treatment for obesity, while sci2sci manages research data and lineage. The firm remains distinct from its Growth Fund and unrelated Superangels namesakes.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.4M 1 disclosed · full round size, not this investor’s share